

Nutrikinetic study of fermented soybean paste (*Cheonggukjang*) isoflavones according to the Sasang typology

Min Jung Kim¹, Da-Hye Lee^{1,2}, Jiyun Ahn^{1,2}, Young-Jin Jang¹, Tae-Youl Ha^{1,2}, Eunju Do³ and Chang Hwa Jung^{1,2,5}

¹Research Division of Food Functionality, Korea Food Research Institute, Wanju-gun, Jeonbuk 55365, Republic of Korea

²Department of Food Biotechnology, Korea University of Science and Technology, Wanju-gun, Jeonbuk 55365, Republic of Korea

³Clinical Trial Convergence Commercialization Team, Korea Medicine Industry Support Center, Daegu Technopark, Susung-gu, Daegu 42158, Republic of Korea

BACKGROUND/OBJECTIVES: In Oriental medicine, certain foods may be beneficial or detrimental based on an individual's constitution; however, the scientific basis for this theory is insufficient. The purpose of this study was to investigate the effect of body constitution, based on the Sasang type of Korean traditional medical classification system, on the bioavailability of soy isoflavones of *Cheonggukjang*, a quick-fermented soybean paste.

SUBJECTS/METHODS: A pilot study was conducted on 48 healthy Korean men to evaluate the bioavailability of isoflavone after ingestion of food based on constitution types classified by the Sasang typology. The participants were classified into the Taeumin (TE; n = 15), Soyangin (SY; n = 15), and Soeumin (SE; n = 18) groups. Each participant ingested 50 g of *Cheonggukjang* per 60 kg body weight. Thereafter, blood was collected, and the soy isoflavone metabolites were analyzed by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Nutrikinetic analysis of individual isoflavone-derived metabolites was performed.

RESULTS: Our nutrikinetic analysis identified 21 metabolites derived from isoflavones in the blood samples from 48 healthy Korean men (age range, 21-29 years). Significant differences were observed in the time to maximum concentration (T_{max}) and elimination half-life ($t_{1/2}$) for nine metabolites among the three groups. The T_{max} and $t_{1/2}$ of the nine metabolites were higher in the SE group than in the other groups. Moreover, the absorption rates, as determined by the area under the plasma-level curve (AUC) values of intact isoflavone, were 5.3 and 9.4 times higher in the TE group than in the SY and SE groups, respectively. Additionally, the highest AUC values for phase I and II metabolites were observed in the TE group.

CONCLUSIONS: These findings indicate that isoflavone bioavailability, following *Cheonggukjang* ingestion, is high in individuals with the TE constitution, and relatively lower in those with the SE and SY constitutions.

Nutrition Research and Practice 2020;14(2):102-108; <https://doi.org/10.4162/nrp.2020.14.2.102>; pISSN 1976-1457 eISSN 2005-6168

Keywords: Nutrikinetics, cheonggukjang, isoflavones, bioavailability, sasang typology

INTRODUCTION

Although traditional Chinese medicine (TCM) is a prominently recognized branch of complementary and alternative medicine (CAM), it is only one of the many forms of CAM practiced worldwide. Other noteworthy forms of CAM include Ayurveda in India, traditional Mongolian medicine, traditional Vietnamese medicine, and Sasang constitutional medicine in Korea [1]. Sasang typology is a traditional Korean classification system that categorizes people into four constitutional types based on the biopsychosocial characteristics, emphasis of the balance between *Yin* (the feminine passive principle, persistence, wetness, cold, darkness) and *Yang* (the masculine active principle, dryness, heat, and light) such as: Soyangin (SY, "lesser yang"), Soeumin (SE, "lesser yin"), Taeumin (TE, "greater yin"), and Taeyangin

(TY, "greater yang") [2]. Sasang typology was first introduced by Jema Lee at the end of the 19th century in his book, *Donguisusebowon* ("Longevity and Life Preservation in Eastern Medicine") [3]. Sasang constitution medicine is type of personalized medicine in which the diseases are diagnosed and treated by categorizing patients into one of the four types based on both body composition and psychological factors [4]. Traditional countries such as China, India, and Korea have had a long history of using food as a substitute for medicine, and several studies have reported that certain foods may be beneficial or detrimental based on an individual's Sasang constitution [5,6]. Furthermore, many Korean individuals turn to herbal and food-based Sasang remedies when modern medicine has fails to improve their health conditions. In a survey of 839 Koreans (55% of men, 45% of women; age range: 20-60 years), 90% of

This research was supported by the Main Research Program of the Korea Food Research Institute (KFRI), funded by the Ministry of Science, ICT, & Future Planning [E0187400-02].

⁵ Corresponding Author: Chang Hwa Jung, Tel. 82-63-219-9301, Fax. 82-63-219-9225, Email. chjung@kfri.re.kr

Received: October 30, 2018, Revised: April 23, 2019, Accepted: November 7, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

the participants were aware of Sasang typology, and approximately 88% believed that they should follow a diet suitable for their body type for the prevention and treatment of disease [7]. However, most of these beliefs are based on information presented in traditional medical texts, raising questions regarding their scientific validity.

Over the last decade, researchers in various fields have applied scientific approaches to Sasang typology, demonstrating that patients with specific constitutions are susceptible to hypertension [8], diabetes [9], sleep apnea [10], and metabolic disorders [11,12]. Additional studies have revealed that, relative to patients with other constitutional types, individuals with the TE constitution exhibit increased body mass, triglycerides, total cholesterol, blood pressure, and risk of metabolic syndrome [13]. Although Sasang typology is primarily concerned with the diagnostic aspects of disease, food intake according to Sasang type is regarded as an important means for preventing the onset and progression of disease. Following pharmacotherapeutic treatment, changes in food intake are often recommended to promote good health in patients with various diseases [14]. Kim *et al.* [15] reported improvement in the level of cholesterol and triglycerides associated with favorable outcomes in patients with hyperlipidemia after food intake according to Sasang typology. An additional study suggested that patients with the SE constitution are more susceptible to sweating, anemia, and flushing following the ingestion of red ginseng [16]. However, the reported association between the Sasang typology and diet differs across studies, and there is minimal scientific evidence supporting the association between the constitutional type of individual and food. In particular, nutrikinetic studies based on Sasang constitution have not been conducted based on food.

Cheonggukjang is a quick-fermented soybean paste used in various Korean foods. Several previous studies have documented the potential health benefits of *cheonggukjang*, including its anti-obesity, anti-oxidant, anti-osteoporotic, and anti-prediabetic effects [17-20]. Although Sasang typology recommends the ingestion of soybeans for patients with the TE constitution, the scientific evidence in support of this recommendation is minimal. In our previous study, we identified and analyzed the nutrikinetics of individual metabolites of isoflavones, metabolized in the blood following the intake of *Cheonggukjang* in an animal model [21]. In addition, we have reported the difference in metabolomic and lipidomic parameters according to Sasang constitution [22]. In the present study, we aimed to determine whether Sasang constitution is associated with the differences in the bioavailability of soy isoflavones derived from *Cheonggukjang*. Sasang constitution was classified using the questionnaire for Sasang Constitutional Classification II (QSCCII) prepared by doctors practicing Oriental medicine. Isoflavone-derived metabolites in the blood were identified using liquid chromatography-tandem mass spectrometry (LC-MS).

SUBJECTS AND METHODS

Participants and study design

Previously, we examined whether the metabolomics and lipidomics analysis of human plasma could classify the Sasang

constitution types in 48 healthy Korean men between the age of 21 and 29 years [22]. The present study measured the bioavailability of soy isoflavone metabolites in blood after the ingestion of *Cheonggukjang*, in the 48 participants from the previously described study. This human study was approved (KMISC-FD-22) by the Daegu Oriental Hospital of Daegu Hanny University (Daegu, South Korea). The analysis was only performed for three constitutions, i.e., TE, SE, and SY because the TY constitution is very rare. Among the Korean population, 20% of SY, 50% of TE, 30% of SE, and below 0.1% of TY were reported [23]. Participants were classified into the TE (n = 15), SY (n = 15), and SE (n = 18) groups by an Oriental medicine doctor based on the QSCC II [24], face, body shape, and voice. Details on participant recruitment are described in the previous study [22]. Briefly, individuals with a body mass index (BMI) < 18.5 kg/m² or > 30 kg/m², hypertension, ALT/AST more than twice the normal upper limit, those participating in other studies, those who donated blood during the past month, and those with chronic diseases were excluded. Participants fasted for 10-17 h prior to the collection of blood samples. Each participant ingested 50 g of *Cheonggukjang* per 60 kg body weight following which blood was collected in an ethylenediaminetetraacetic acid containing plasma tubes at different time points (0.5 h, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h). The daily intake of *Cheonggukjang* was determined by referring to the top 10 products of the NAVER (<https://www.naver.com>) search and the average intake was about 50 g. The blood samples were centrifuged at 1,550 × g for 10 min at 4°C. Thereafter, the plasma was separated and stored at -80°C until analysis. The *Cheonggukjang* used in this study is the same as the one used in our previous work, and comprised > 90% isoflavone aglycones, such as genistein and daidzein [21].

Sample preparation and LC-MS/MS analysis

Plasma proteins were precipitated with cold methanol. After mixing for 30 min at 4°C, the samples were centrifuged at 10,000 rpm for 10 min at 4°C. The supernatant was dissolved in 50% aqueous methanol containing caffeine for ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF) analysis. UPLC-MS analysis was performed using an Acquity UPLC system (Waters, Miliford, MA, USA) coupled to an Waters SYNAPT G2-Sir mass spectrometer (Waters Corp., Manchester, UK). Chromatographic separation of samples was performed on ACQUITY UPLC BEH C18 (2.1 × 100 mm, 1.7 μm) column was used with a column temperature of 40°C and flow rate of 0.35 mL/min. The mobile phase A constituted water with 10 mM ammonium acetate, and mobile phase B constituted acetonitrile with 0.1% formic acid. The gradient conditions were 0.5% B rising to 70% in 18 min; thereafter, to a maximum of 99.5% after 1 min, and subsequently, equilibrated at 0.5% B for 1 min. The auto-sampler was conditioned at 4°C and the injection volume was set to 5 μL. The Q-TOF-MS was operated in negative electrospray ionization mode, with a scan range of m/z 50-1,000. The cone voltage was 30 V, capillary voltage was 1 kV, and scan time was 0.2s, with an interscan delay of 0.02s. The source temperature was set at 120°C, while the desolvation flow was set to 800 L/h; the desolvation gas temperature was set at 500°C. The MS was

calibrated using sodium formate to ensure accuracy, and leucine enkephalin was injected as a lock mass at a concentration of 200 μ M and flow rate of 5 μ L/min. The detected values were corrected simultaneously and independently. In the MS-MS experiments, argon was used as the collision gas, with the collision energy alternating between 25 and 45 eV.

Identification of isoflavone metabolites

UNIFI software (ver. 1.7.1, Waters, Manchester, UK) was used for LC-MS/MS data collection, data mining, and library searching. After detecting the peak of a complex matrix, a componentization process was performed to create a single spectrum representing the peak, and to organize the unrelated spectra. Spectrum- and structure-matching were performed to identify the metabolites after obtaining information on the MS value, adduct, and high and low energy components with a specific retention time. In the quantitative analysis of isoflavone metabolites, the height of each peak was used to measure the intensity. Analytical validation was based on the exact mass and retention time of standard compounds.

Genistein (G6776), daidzein (16587), and glycitein (G2785) were purchased from Sigma-Aldrich (St Louis, MO, USA). Daidzein 4'-glucuronide (D103490), daidzein 7-glucuronide (D103510), daidzein 4'-sulfate (D103520), genistein 7-glucuronide (G350015), genistein diglucuronide (G350055), genistein 4'-sulfate (G350045), daidzein 7-sulfate 4'-glucuronide (D103565), daidzein diglucuronide (D103575), genistein 7-glucuronide-4'-sulfate (G350050), and genistein 7-sulfate (G350045) were purchased from Toronto Research Chemicals (Toronto, Ontario, Canada). Dihydrogenistein (sc-498873), equol 7-glucuronide (sc-219699), and equol 4'-sulfate (sc-219698) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). O-desmethylangolensin (ODMA) was

purchased from Plantech UK (Reading, Berkshire, UK). 2-hydroxygenistein (GFN99257) was purchased from ChemFaces (Wuhan, China). 3-hydroxydaidzein (1309) was purchased from Extrasynthese (Geray, France). Dihydrodaidzein sulfate and 5-hydroxyequol were identified putatively based on accurate mass and MS/MS fragments.

Nutritional analyses

Nutritional analyses for each isoflavone-derived metabolite collected from individual subjects was performed using non-compartmental methods and nutritional parameters, including the maximum peak area (PA) (C_{max}), time to reach C_{max} (T_{max}), terminal elimination half-time ($t_{1/2}$), and the area under the curve of the metabolite peak area versus time ($AUC_{0-24\text{ h}}$) were calculated using PK solutions ver. 2.0 (Summit Research Services, Montrose, CO, USA) [21].

Statistical analysis

All data (C_{max} , T_{max} , $t_{1/2}$, and AUC) are expressed as mean \pm SEM, and analyzed using one-way analyses of variance (ANOVA) followed by comparison of Duncan's multiple post-hoc analysis. Differences among groups were considered statistically significant at $P < 0.05$ and are indicated by different lowercase letters. All statistical analyses were analyzed using SPSS ver. 20 (IBM, Armonk, New York, United States).

RESULTS

Identification of isoflavone metabolites

The levels of isoflavone metabolites in the participants' blood samples after the ingestion of *Cheonggukjang* were analyzed by UPLC-QTOF-MS. A total of 21 isoflavone metabolites were

Table 1. Isoflavone metabolites identified in the plasma following *Cheonggukjang* ingestion

No		Metabolites	Exact mass (m/z)	Actual mass (m/z)	Mass error (mDa)	RT (min)	MS fragments
1	Intact isoflavones	Daidzein	253.0501	253.0499	-2.20	7.44	195
2		Genistein	269.045	269.0455	0.5	8.80	224, 201, 183
3		Glycitein	283.0606	283.0613	0.7	6.46	269, 266, 240
4	Phase I metabolites	3-hydroxydaidzein	269.045	269.0473	2.3	5.26	253
5		2-hydroxygenistein	285.0399	285.0425	-1.55	8.17	269
6	Phase II metabolites	Daidzein 4'-glucuronide	429.0822	429.0894	7.2	3.85	253
7		Daidzein 7-glucuronide	429.0822	429.0826	0.4	5.02	253
8		Daidzein diglucuronide	605.1143	605.1157	1.4	2.85	429, 253
9		Daidzein 4'-sulfate	333.0069	333.0071	0.2	6.34	253
10		Daidzein 7-sulfate 4'-glucuronide	509.039	509.0398	0.8	4.55	253
11		Genistein-7-glucuronide	445.0771	445.0790	1.9	5.92	300, 269, 206,134
12		Genistein diglucuronide	621.1092	621.1094	0.24	2.93	445, 269
13		Genistein 7-glucuronide 4'-sulfate	525.0339	525.0346	0.70	4.53	349, 269, 224, 133
14		Genistein 4'-sulfate	349.0018	349.0023	0.48	6.6	269, 224, 133
15	Genistein 7-sulfate	349.0018	349.0019	0.1	7.48	349, 269	
16	Gut-mediated metabolites	Dihydrogenistein	271.0606	271.0600	-0.6	8.82	165
17		Dihydrodaidzein sulfate	335.0225	335.0237	1.2	6.50	253
18		Equol-7-glucuronide	417.1186	417.1180	-0.6	5.52	241, 175, 113
19		Equol-4'-sulfate	321.0433	321.0420	-1.31	7.24	241, 135, 119
20		5-hydroxy equol	257.0814	257.0459	2.6	7.44	257, 151, 105
21		O-Desmethylangolensin	257.0814	257.0866	5.2	9.64	257

MS, mass spectrometry; RT, retention time; m/z, mass/charge.

identified based on retention time, molecular weight, and fragment ions when compared to authenticated standards (Table 1) such as: intact isoflavone (n = 3), phase I metabolites (n = 2), phase II metabolites (n = 10), and gut-mediated metabolites (n = 6).

Nutrikinetik analysis of isoflavone metabolites according to sasang constitution

Significant differences ($P < 0.05$) in the time to reach maximum concentration (T_{max}) were observed among the SE, SY, and TE

Table 2. T_{max} and $t_{1/2}$ of isoflavone metabolites identified in the plasma following *Cheonggukjang* ingestion according to Sasang typology.

No	Isoflavone metabolites	T_{max} (h)				$t_{1/2}$ (h)			
		SE	SY	TE	P-value	SE	SY	TE	P-value
1	Daidzein	1.35 ± 0.76 ^b	1.13 ± 0.34 ^{ab}	0.73 ± 0.40 ^a	0.012	5.8 ± 3.59	4.03 ± 2.35	4.45 ± 2.58	0.246
2	Genistein	2.5 ± 2.52	2.33 ± 3.19	0.8 ± 0.87	0.121	10.15 ± 7.3	8.03 ± 6.93	9.76 ± 6.15	0.714
3	Glycitein	2 ± 2.54 ^b	1.07 ± 0.25 ^{ab}	0.53 ± 0.12 ^a	0.038	10.92 ± 5.49 ^b	11.26 ± 6.33 ^b	6.19 ± 3.37 ^a	0.029
4	3-hydroxydaidzein	3.66 ± 2.57	8 ± 2.83	7.14 ± 7.32	0.356	5.48 ± 1.87 ^b	0.92 ± 0.59 ^a	0.92 ± 1.37 ^a	0.000
5	2-hydroxygenistein	9.14 ± 6.41 ^b	2.6 ± 3.74 ^a	2.57 ± 3.81 ^a	0.000	18.95 ± 15.91	16.08 ± 14.76	26.0 ± 31.95	0.576
6	Daidzein 4'-glucuronide	2.11 ± 2.21	1.07 ± 0.25	2.27 ± 2.06	0.159	5.67 ± 4.95	3.51 ± 2.64	7.39 ± 8.57	0.225
7	Daidzein 7-glucuronide	3.89 ± 3.03 ^b	1.2 ± 0.4 ^a	2.5 ± 1.82 ^{ab}	0.004	4.51 ± 4.59	4.90 ± 2.85	3.27 ± 4.65	0.564
8	Daidzein diglucuronide	2.89 ± 0.99	2.43 ± 0.82	2.27 ± 0.68	0.118	1.87 ± 1.34 ^b	1.40 ± 1.14 ^b	0.46 ± 0.26 ^a	0.002
9	Daidzein 4'-sulfate	1.5 ± 0.5 ^b	1 ± 0 ^a	0.83 ± 0.39 ^a	0.000	4.76 ± 3.2	4.95 ± 3.03	4.59 ± 2.67	0.951
10	Daidzein 7-sulfate 4'-glucuronide	10.83 ± 5.68 ^b	9 ± 7.07 ^b	3.23 ± 3.57 ^a	0.002	2.99 ± 1.42 ^{ab}	5.89 ± 4.98 ^b	2.49 ± 4.31 ^a	0.060
11	Genistein 7-glucuronide	1.61 ± 0.49	1.67 ± 1.74	2.07 ± 2.37	0.724	5.98 ± 5.04 ^b	3.99 ± 4.30 ^{ab}	1.91 ± 2.29 ^a	0.045
12	Genistein diglucuronide	5.67 ± 2.52 ^b	4.29 ± 2.91 ^{ab}	3.6 ± 1.96 ^a	0.072	8.1 ± 2.39 ^{ab}	8.95 ± 5.12 ^b	6.07 ± 1.96 ^a	0.083
13	Genistein-7-glucuronide-4'-sulfate	5.67 ± 3.77 ^b	5.71 ± 4.27 ^b	1.77 ± 1.01 ^a	0.003	4.05 ± 3.7 ^{ab}	1.99 ± 3.27 ^a	11.58 ± 17.32 ^b	0.061
14	Genistein 4'-sulfate	5.47 ± 6.2	1.53 ± 0.5 ^a	-	0.024	6.69 ± 8.01	13.65 ± 5.28 ^a	-	0.017
15	Genistein-7-sulfate	-	-	1.03 ± 0.53	0.000	-	-	5.48 ± 4.5	0.000
16	Dihydrogenistein	15.18 ± 7.97	13.46 ± 7.44	11.1 ± 8.95	0.401	7.57 ± 5.72	3.61 ± 3.40	9.56 ± 8.79	0.127
17	Dihydrodaidzein sulfate	11.86 ± 8.95	9.67 ± 1.97	9.33 ± 5.35	0.539	24.39 ± 8.63 ^b	4.53 ± 2.44 ^a	4.37 ± 2.86 ^a	0.000
18	Equol-7-glucuronide	16.33 ± 6.62 ^b	9 ± 8.92 ^a	7.92 ± 6.26 ^a	0.020	6.32 ± 1.46 ^a	19.15 ± 12.66 ^b	6.16 ± 8.22 ^a	0.010
19	Equol-4-sulfate	-	-	5.33 ± 3.59	0.000	-	-	0.52 ± 0.32	0.000
20	5-hydroxy equol	11.5 ± 5.07	4.8 ± 3.71	11.61 ± 7.32	0.137	2.17 ± 0.87	0.73 ± 0.36	1.78 ± 1.31	0.153
21	O-Desmethylangolensin	11.11 ± 3.66	7.81 ± 6.38	10.27 ± 2.82	0.140	4.81 ± 5.11	3.32 ± 3.15	4.36 ± 3.69	0.665

SE, *Soeumin*; SY, *Soyangin*; TE, *Taeumin*; T_{max} , time to maximum concentration; $t_{1/2}$, elimination half-life; -, cannot be calculated. Differences among the groups were analyzed by Duncan's multiple range test ($P < 0.05$) and are indicated by different lowercase letters. Letter "a" is significant to "b", but "ab" is not significant.

Table 3. C_{max} of isoflavone metabolites identified in the serum following *Cheonggukjang* ingestion according to Sasang typology.

No	Metabolites	SE	SY	TE	P-value
1	Daidzein	7,791.4 ± 2,319.2 ^a	6,024.4 ± 2,337.6 ^a	212,365.8 ± 105,648.9 ^b	0.000
2	Genistein	3,049.1 ± 1,154.6 ^a	30,845.2 ± 24,189.8 ^b	91,486.0 ± 40,030.0 ^c	0.000
3	Glycitein	4,023.1 ± 1,207.3 ^a	4,022.0 ± 634.3 ^a	9,698.0 ± 2,747.5 ^b	0.000
4	3-hydroxydaidzein	5,557.2 ± 3,134.4	1,265.8 ± 833.0	5,130.5 ± 6,759.7	0.197
5	2-hydroxygenistein	8,083.9 ± 7,713.2 ^b	3,372.8 ± 1,227.1 ^a	8,782.5 ± 6,066.0 ^b	0.034
6	Daidzein 4'-glucuronide	8,602.4 ± 2,767.0 ^b	4,904 ± 1,261.5 ^a	7,787.8 ± 1,863.5 ^b	0.000
7	Daidzein 7-glucuronide	9,488.5 ± 3,506.4 ^b	6,606.1 ± 1,570.6 ^a	8,003.2 ± 1,835.9 ^{ab}	0.011
8	Daidzein diglucuronide	2,612.1 ± 654.4 ^b	1,312.9 ± 326.0 ^a	2,819.7 ± 2,767.2 ^b	0.033
9	Daidzein 4'-sulfate	4,269.3 ± 1,481.3 ^a	2,12315.8 ± 57,165.3 ^b	715,000.9 ± 179,329.6 ^c	0.000
10	Daidzein 7-sulfate 4'-glucuronide	1,807.3 ± 861.1	1,802.0 ± 476.0	2,312.6 ± 661.0	0.088
11	Genistein 7-glucuronide	9,830.3 ± 2,876.4 ^b	7,452.9 ± 1,717.9 ^a	8,344.0 ± 2,033.2 ^{ab}	0.021
12	Genistein diglucuronide	7,298.4 ± 4,149.6 ^b	2,913.6 ± 1,157.0 ^a	2,848.8 ± 653.9 ^a	0.000
13	Genistein-7-glucuronide-4'-sulfate	12,963.1 ± 8,084.3 ^b	3,803.8 ± 3,398.6 ^a	6,833.1 ± 2,075.4 ^a	0.000
14	Genistein 4'-sulfate	11,294.5 ± 14,782.8	9,518.8 ± 2,631.0	-	0.659
15	Genistein-7-sulfate	-	-	126,029.3 ± 100,712.1	0.000
16	Dihydrogenistein	3,436.8 ± 3,261.7	12,123.7 ± 21,125.4	7,928.6 ± 13,903.9	0.290
17	Dihydrodaidzein sulfate	804.1 ± 488.7 ^a	24,384.5 ± 15,160.6 ^a	94,131.3 ± 72,667.6 ^b	0.000
18	Equol-7-glucuronide	9,534.7 ± 7,255.4 ^b	468.3 ± 256.9 ^a	3,553.9 ± 3,938.9 ^a	0.000
19	Equol-4-sulfate	-	-	5,692.0 ± 3,434.8	0.000
20	5-hydroxy equol	2,537.7 ± 1,854.1	1,351.2 ± 584.0	1,900.0 ± 1,741.7	0.482
21	O-Desmethylangolensin	3,206.8 ± 2,665.2 ^b	1,181.2 ± 669.1 ^a	2,803.0 ± 1,426.5 ^b	0.019

SE, *Soeumin*; SY, *Soyangin*; TE, *Taeumin*; C_{max} , maximum peak area; -, cannot be calculated. Differences among the groups were analyzed by Duncan's multiple range test ($P < 0.05$) and are indicated by different lowercase letters. Letter "a" is significant to "b" and "c", but "ab" is not significant.

Table 4. AUC_(0-24 h) of isoflavone metabolites identified in the serum following *Cheonggukjang* ingestion according to Sasang typology.

No	Metabolites	SE	SY	TE	P-value
1	Daidzein	56,399 ± 18,774.20 ^a	29,480.4 ± 11,280.24 ^a	748,491.8 ± 282,494.31 ^b	0.000
2	Genistein	19,846.56 ± 8,312.65 ^a	143,137.6 ± 67,995.08 ^b	298,415.4 ± 116,138.76 ^c	0.000
3	Glycitein	41,912.94 ± 11,314.79 ^a	37,019.47 ± 7,346.46 ^a	69,566.33 ± 23,136.25 ^b	0.000
4	3-hydroxydaidzein	20,177 ± 8,951.96	7,286.25 ± 2,772.5	22,049.67 ± 30,174.84	0.349
5	2-hydroxygenistein	116,443.47 ± 108,650.35 ^b	36,360.2 ± 12,293.57 ^a	82,759.93 ± 63,820.57 ^{ab}	0.020
6	Daidzein 4'-glucuronide	59,741.29 ± 17,786.70 ^b	30,414.13 ± 7,265.75 ^a	50,585 ± 14,090.84 ^b	0.000
7	Daidzein 7-glucuronide	80,745.78 ± 29,501.35 ^b	50,427.4 ± 11,690.16 ^a	57,662.07 ± 24,969.74 ^a	0.002
8	Daidzein diglucuronide	20,737.39 ± 6,555.99 ^b	11,543 ± 4,877.33 ^a	9,518.27 ± 3,777.76 ^a	0.000
9	Daidzein 4'-sulfate	23,419.39 ± 7,387.22 ^a	974,579.67 ± 340,431.08 ^b	3,244,240.93 ± 1,063,972.11 ^c	0.000
10	Daidzein 7-sulfate 4'-glucuronide	14,362.5 ± 8,030.20 ^a	24,555.67 ± 6,302.61 ^b	20,541.47 ± 9,702.07 ^b	0.004
11	Genistein 7-glucuronide	64,426.39 ± 34,285.58	46,780.2 ± 21,151.31	43,054.73 ± 24,714.20	0.081
12	Genistein diglucuronide	82,762.56 ± 26,491.63 ^b	34,285.87 ± 15,499.38 ^a	34,636.87 ± 5,952.47 ^a	0.000
13	Genistein-7-glucuronide-4'-sulfate	121,239.39 ± 88,332.07 ^b	35,797.64 ± 27,104.94 ^a	46,511.2 ± 13,365.33 ^a	0.000
14	Genistein 4'-sulfate	78,567.89 ± 138,035.16	82,584.8 ± 21,945.13	-	0.000
15	Genistein-7-sulfate	-	-	243,616.87 ± 133,245.66	0.000
16	Dihydrogenistein	37,918.76 ± 34,160.86	85,911.36 ± 191,426.6	35,885.33 ± 25,312.26	0.404
17	Dihydrodaidzein sulfate	11,347.2 ± 7,347.72 ^a	230,100.3 ± 139,539.94 ^a	971,317.79 ± 640,145.02 ^b	0.000
18	Equol-7-glucuronide	101,393.3 ± 67,588.67 ^b	6,555.06 ± 3,139.22 ^a	43,767.85 ± 62,165.99 ^a	0.001
19	Equol-4-sulfate	-	-	35,441.67 ± 46,701.94	0.000
20	5-hydroxy equol	22,188.88 ± 31,641.4	8,758.6 ± 4,929.73	20,178.89 ± 17,117.64	0.593
21	O-Desmethylangolensin	33,917.38 ± 26,354.99 ^b	13,765.62 ± 7,491.53 ^a	30,201.8 ± 14,449.10 ^b	0.019

SE, *Soeumin*; SY, *Soyangin*; TE, *Taeumin*; AUC_(0-24 h), area under the curve of the metabolite peak area versus time; -, cannot be calculated. Differences among the groups were analyzed by Duncan's multiple range test ($P < 0.05$) and are indicated by different lowercase letters. Letter "a" is significant to "b" and "c", but "ab" is not significant.

groups for nine isoflavone metabolites (Table 2). The high T_{max} (h) values for the metabolites were observed in the SE group compared to the SY and TE groups. In addition, the fastest rate of metabolite decay was observed in the TE group, with the exception of those for genistein 7-glucuronide-4'-sulfate and equol-7-glucuronide. Significant differences in the maximum metabolite concentrations (C_{max}) of 15 metabolites were observed among the three groups (Table 3). Notably, the mean C_{max} of intact isoflavones in the TE group was 21 times higher than that in the SE group and 7.7 times higher than that in the SY group. The C_{max} values of most isoflavone metabolites were significantly lower ($P < 0.05$) in the SY group than in the remaining two groups. The area under the plasma level-time curve (AUC_(0-24 h)) represents the total amount of active drug that reaches the systemic circulation, reflecting the bioavailability of the drug. The AUC_(0-24 h) values for intact isoflavones were 5.3 and 0.4 times higher in the TE group than in the SY and SE groups, respectively (Table 4). AUC_(0-24 h) values for phase I metabolites were significantly higher ($P < 0.05$) in the TE and SE groups than in the SY group. In contrast, the AUC values for phase II metabolites were 2.7 and 6.4 times higher in the TE group than in the SY and SE groups, respectively. In particular, daidzein 4-sulfate was the most representative phase II metabolite in the TE group. The AUC_(0-24 h) of genistein-derived metabolites were found to be relatively high in the SE group. Equol-7-glucuronide was detected in all three groups, while equol-4-sulfate was detected only in the TE group. The levels of equol metabolites were lower in the SY group than in the TE and SE groups.

DISCUSSION

In our previous study, we investigated the probable classification of Sasang constitution through metabolomics and lipidomics analysis from human blood, and have proposed several candidate metabolites representative of the Sasang constitution [22]. In this study, we aimed to investigate the change in the bioavailability of functional ingredients after the ingestion of food according to Sasang typology. To validate this hypothesis, we investigated the differences in the bioavailability of soy isoflavones after the intake of *Cheonggukjang* in the same cohort of participants used in the previous study. The participants in the present study exhibited significant differences among the three groups for body mass index (BMI), body fat percentage (BFP), waist-to-hip ratio (WHR), and systolic blood pressure (SBP) [22]. Especially, the BMI, BFP, VFA, and SBP were higher in the TE and SY groups than in the SE group. In Sasang typology, individual with the SE constitution were found to be thinner than those in the SY and TE groups [1].

Sasang typology is not only used for the treatment of diseases but also for their prevention, since a specific diet is often recommended to each patient based on his or her constitutional type. Studies have been conducted on the treatment or prevention of diseases using a variety of diets to determine the correlation between diet and Sasang constitution [25]. Most dietary studies concerning Sasang constitution have investigated its relationship with diseases; however, no studies have attempted to identify the association of the bioavailability of functional ingredients according to Sasang typology. Nutritional analyses are required to determine the differential




Fig. 1. Overview of T_{max} (h), $t_{1/2}$ (h), C_{max} , and $AUC_{(0-24\text{ h})}$ for 21 isoflavone metabolites detected in the plasma following ingestion of *Cheonggukjang* according to sasang typology. Error bars represent the mean \pm SEM (* $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$). SE, *Soeumin*; SY, *Soyangin*; TE, *Taeumin*; $AUC_{(0-24\text{ h})}$: area under the curve of the metabolite peak area versus time; T_{max} , time to maximum concentration; $t_{1/2}$, elimination half-life; C_{max} , maximum peak area.

mechanism, absorption, distribution, and excretion of same functional groups from the same food function in patients with different constitutions. Our recent *in vivo* studies have demonstrated that the bioavailability of functional ingredients following the ingestion of the same food may differ depending on health conditions, even when the food is ingested in the same form [21,26]. Therefore, the bioavailability of functional ingredients of food are important in the treatment or prevention of diseases [27].

Cheonggukjang is one of the most commonly consumed fermented soybean pastes in Korea, and soy isoflavones and saponins are its well-known functional ingredients [28]. In Sasang constitutional medicine, soybean and soybean products including *Cheonggukjang*, is considered more suitable for individuals with the TE constitution, as it is thought to eliminate moisture from the body, improve circulation, and enhance healing [29]. In the present study, the AUC-indicated bioavailability of intact isoflavones (genistein, daidzein, and glycitein) and total metabolites was significantly higher in the TE group than in the SY and EY groups (Fig. 1). The increased bioavailability of *Cheonggukjang* isoflavones may contribute to health improvement in individuals with the TE constitution. In addition, the levels of equol metabolites were lower in the SY group than

in the SE and TE groups. Equol is one of the metabolites produced by the bacteria present in the intestinal tract of subjects ingesting soy-containing isoflavones [30]. It is also worth considering if the observed effect was mediated by Sasang constitution on intestinal microbial environment. High isoflavone bioavailability may indicate that isoflavones exhibit greater efficacy in individuals with the TE constitution. Although the bioavailability of isoflavones, as determined by nutrkinetic analyses is insufficient to adequately characterize patients into different constitutional types, the analyses of bioavailability may help explain the association between Sasang constitution and diet.

There are some limitations to this study. First, the participant cohort was small and unsuitable for validating the association between diet and Sasang constitution-based system of classification. Therefore, current evidence on the bioavailability of isoflavones in *Cheonggukjang* is limited. Second, the objective nature and scientific reproducibility of the Sasang constitution is controversial. Third, additional evidence is needed to ascertain if Sasang constitution can be used as a measure for assessing the bioavailability and constitution of dietary isoflavones observed in plasma after the ingestion of *Cheonggukjang*.

In conclusion, our results indicate that the overall bioavailability

of isoflavone metabolites, after the ingestion of *Cheonggukjang*, was higher in the TE group than in the other two groups. Data on the bioavailability of functional ingredients according to Sasang typology might be useful for recommending appropriate diet for the prevention of disease, emphasizing on the functional aspects of oriental medicine.

CONFLICT OF INTEREST

The authors declare no potential conflicts of interest.

ORCID

Min Jung Kim: <https://orcid.org/0000-0002-8894-8538>
 Da-Hye Lee: <https://orcid.org/0000-0001-8144-6992>
 Jiyun Ahn: <https://orcid.org/0000-0002-5930-2957>
 Young-Jin Jang: <https://orcid.org/0000-0003-0553-2498>
 Tae-Youl Ha: <https://orcid.org/0000-0001-7583-9490>
 Eunju Do: <https://orcid.org/0000-0003-2547-0036>
 Chang Hwa Jung: <https://orcid.org/0000-0002-1076-750X>

REFERENCES

1. Yoo J, Lee E, Kim C, Lee J, Lixing L. Sasang constitutional medicine and traditional Chinese medicine: a comparative overview. *Evid Based Complement Alternat Med* 2012;2012:980807.
2. Kim JY, Pham DD. Sasang constitutional medicine as a holistic tailored medicine. *Evid Based Complement Alternat Med* 2009;6 Suppl 1:11-9.
3. Shin S, Kim YH, Hwang MW. Diagnosis and treatment principle in *Sasang* medicine: original symptom. *Integr Med Res* 2016;5:99-104.
4. Lee J, Jung Y, Yoo J, Lee E, Koh B. Perspective of the human body in *sasang* constitutional medicine. *Evid Based Complement Alternat Med* 2009;6 Suppl 1:31-41.
5. Kim JY, Kim CW, Koh BH, Song IB. Justification and usage of food classification according to body constitution. *J Sasang Const Med* 1995;7:263-79.
6. Lee CH. Health concept in traditional Korean diet, in therapeutic use of foods in East Asia. *Korean Korean Am Stud Bull* 1998;9:8-18.
7. Lee CH. Harmonization of eastern and western health knowledge; nutrigenetics and *Sasang* typology. *Food Sci Technol Res* 2007; 13:89-95.
8. Lee J, Lee J, Lee E, Yoo J, Kim Y, Koh B. The *Sasang* constitutional types can act as a risk factor for hypertension. *Clin Exp Hypertens* 2011;33:525-32.
9. Cho NH, Kim JY, Kim SS, Lee SK, Shin C. Predicting type 2 diabetes using *Sasang* constitutional medicine. *J Diabetes Investig* 2014;5: 525-32.
10. Lee SK, Yoon DW, Yi H, Lee SW, Kim JY, Shin C. Tae-eum type as an independent risk factor for obstructive sleep apnea. *Evid Based Complement Alternat Med* 2013;2013:910382.
11. Choi K, Lee J, Yoo J, Lee E, Koh B, Lee J. *Sasang* constitutional types can act as a risk factor for insulin resistance. *Diabetes Res Clin Pract* 2011;91:e57-60.
12. Lee SK, Yoon DW, Lee SW, Kim JY, Kim JK, Shin C. Non-alcoholic fatty liver disease among *sasang* constitutional types: a population-based study in Korea. *BMC Complement Altern Med* 2015;15:399.
13. Lee TG, Koh B, Lee S. *Sasang* constitution as a risk factor for diabetes mellitus: a cross-sectional study. *Evid Based Complement Alternat Med* 2009;6 Suppl 1:99-103.
14. Moon HJ, Jung SJ. Nursing approach of four constitutional theory. *J Korea Community Health Nurs Acad Soc* 1996;10:139-54.
15. Kim YY, Choue R, Song IB, Lee EJ. The clinical effect of *Sasang* constitutional diets for the hypercholesterolemic patients. *Korean J Nutr* 2000;33:824-32.
16. Yang M, Lee HS, Hwang MW, Jin M. Effects of Korean red ginseng (*Panax Ginseng Meyer*) on bisphenol A exposure and gynecologic complaints: single blind, randomized clinical trial of efficacy and safety. *BMC Complement Altern Med* 2014;14:265.
17. Choi JH, Pichiah PB, Kim MJ, Cha YS. *Cheonggukjang*, a soybean paste fermented with *B. licheniformis*-67 prevents weight gain and improves glycemic control in high fat diet induced obese mice. *J Clin Biochem Nutr* 2016;59:31-8.
18. Kang SJ, Seo JY, Cho KM, Lee CK, Kim JH, Kim JS. Antioxidant and neuroprotective effects of *Doenjang* prepared with *Rhizopus*, *Pichia*, and *Bacillus*. *Prev Nutr Food Sci* 2016;21:221-6.
19. Wu WJ, Lee HY, Lee GH, Chae HJ, Ahn BY. The antiosteoporotic effects of *Cheonggukjang* containing vitamin K2 (menaquinone-7) in ovariectomized rats. *J Med Food* 2014;17:1298-305.
20. Lee SY, Park SL, Hwang JT, Yi SH, Nam YD, Lim SI. Antidiabetic effect of *Morinda citrifolia* (Noni) fermented by *Cheonggukjang* in KK-A(y) diabetic mice. *Evid Based Complement Alternat Med* 2012;2012:163280.
21. Lee DH, Kim MJ, Ahn J, Lee SH, Lee H, Kim JH, Park SH, Jang YJ, Ha TY, Jung CH. Nutrikinetics of isoflavone metabolites after fermented soybean product (*Cheonggukjang*) ingestion in ovariectomized mice. *Mol Nutr Food Res* 2017;61.
22. Kim MJ, Lee DH, Ahn J, Ha TY, Jang YJ, Do E, Jung CH. A pilot study on characteristics of metabolomics and lipidomics according to *Sasang* constitution. *Evid Based Complement Alternat Med* 2018;2018:9214960.
23. Lee SJ, Park SH, Cloninger CR, Kim YH, Hwang M, Chae H. Biopsychological traits of *Sasang* typology based on *Sasang* personality questionnaire and body mass index. *BMC Complement Altern Med* 2014;14:315.
24. Kim SH, Lee Y, Koh BH, Jang E. Assessing the diagnostic accuracy of the questionnaire for *Sasang* constitutional classification II (QSCC II): a systematic review. *Eur J Integr Med* 2013;5:393-8.
25. Kim EJ, Choue R, Song IB. The food classification in *Sasang* constitution and effects of Tae-um constitutional diet on the blood biochemical parameters and health status. *Korean J Nutr* 1999; 32:827-37.
26. Lee DH, Kim MJ, Song EJ, Kim JH, Ahn J, Nam YD, Jang YJ, Ha TY, Jung CH. Nutrikinetic study of genistein metabolites in ovariectomized mice. *PLoS One* 2017;12:e0186320.
27. Coll AP, Farooqi IS, O'Rahilly S. The hormonal control of food intake. *Cell* 2007;129:251-62.
28. Shin D, Jeong D. Korean traditional fermented soybean products: *Jang*. *J Ethn Food* 2015;2:2-7.
29. Lee BH, Kwon KB, Han JH, Ryu DG. Bibliographical study on the constitutional foods in Korean medicine. *Korean J Orient Physiol Pathol* 2009;23:1207-20.
30. Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. *Exp Biol Med (Maywood)* 2005;230:155-70.